Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Kayser, Gian ^a   Csanadi, Agnes ^a   Otto, Claudia ^a   Plönes, Till ^a   Bittermann, Nicola ^a   Rawluk, Justyna ^a   Passlick, Bernward ^a   Werner, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; PROTEIN P63; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; VIMENTIN;

ADENOCARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER TISSUE; CONTROLLED STUDY; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECONOMIC ASPECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RELIABILITY; SAMPLE SIZE; SIMULATION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL; TISSUE MICROARRAY; TUMOR BIOPSY;

AGED; ANTIGENS, CD56; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOGRANIN A; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; NUCLEAR PROTEINS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; SYNAPTOPHYSIN; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VIMENTIN;

EID: 84873886998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056333     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Travis WD, Brambilla E, Mueller-Hermelink HK, Harris CC, editors (2004) Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARCPress.
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
4. Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, et al. (2011) 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 29: 3825-3831.
5. de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C, (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73: 1-10.
6. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, et al. (2010) Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 65: 39-59.
7. Mukhopadhyay S, Katzenstein AL, (2011) Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 35: 15-25.
8. Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, et al. (2011) Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 6: 1039-1049.
9. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
10. Sterlacci W, Savic S, Schmid T, Oberaigner W, Auberger J, et al. (2012) Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact. Am J Clin Pathol 137: 946-956.
11. Yanagita E, Imagawa N, Ohbayashi C, Itoh T, (2011) Rapid Multiplex Immunohistochemistry Using the 4-antibody Cocktail YANA-4 in Differentiating Primary Adenocarcinoma From Squamous Cell Carcinoma of the Lung. Appl Immunohistochem Mol Morphol.
12. Gollard R, Jhatakia S, Elliott M, Kosty M, (2010) Large cell/neuroendocrine carcinoma. Lung Cancer 69: 13-18.
13. Rekhtman N, (2010) Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134: 1628-1638.
14. Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, et al. (2012) Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer.
15. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours (UICC International Union Against Cancer). Chichester: John Wiley & Sons.
16. Bryant AS, Cerfolio RJ, Minnich DJ, (2012) Survival and quality of life at least 1 year after pneumonectomy. J Thorac Cardiovasc Surg 144: 1139-1145.
17. Menna C, Ciccone AM, Ibrahim M, Andreetti C, D'Andrilli A, et al. (2012) Pneumonectomy: quality of life and long-term results. Minerva Chir 67: 219-226.
18. Rodriguez KA, Guitron J, Hanseman DJ, Williams V, Starnes SL, (2012) Adjuvant Chemotherapy and Age-Related Biases in Non-Small Cell Lung Cancer. Ann Thorac Surg.
19. Rueth NM, Parsons HM, Habermann EB, Groth SS, Virnig BA, et al. (2011) The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a population-based survival analysis. Ann Surg 254: 368-374.
20. Noh S, Shim H, (2012) Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Lung Cancer 76: 51-55.
21. Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, et al. (2011) Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol 35: 678-686.
22. Husmann G, Kaatsch P, Katalinic A, Bertz J, Haberland J, et al. (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends.: Robert-Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland.
23. Andrews J, Yeh P, Pao W, Horn L, (2011) Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J 17: 104-113.
24. Martin Ureste M, Girones Sarrio R, Montalar Salcedo J, (2010) Biomarkers in bronchopulmonary cancer. Clin Transl Oncol 12: 92-99.
25. Konopa K, (2010) Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer? Ann Oncol 21 Suppl 7: vii199-202.
26. Aggarwal C, Somaiah N, Simon GR, (2010) Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw 8: 822-832.
27. Coate LE, John T, Tsao MS, Shepherd FA, (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10: 1001-1010.
28. Chen Y, Cui T, Yang L, Mireskandari M, Knoesel T, et al. (2011) The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology 80: 333-340.
29. Righi L, Graziano P, Fornari A, Rossi G, Barbareschi M, et al. (2011) Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 117: 3416-3423.
30. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, et al. (2012) p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25: 405-415.
31. Nonaka D, (2012) A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 36: 895-899.
32. Travis WD, (2010) Advances in neuroendocrine lung tumors. Ann Oncol 21 Suppl 7: vii65-71.
33. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, et al. (2007) Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am J Surg Pathol 31: 26-32.
34. La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, et al. (2010) TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457: 497-507.
35. Coghlin CL, Smith LJ, Bakar S, Stewart KN, Devereux GS, et al. (2010) Quantitative analysis of tumor in bronchial biopsy specimens. J Thorac Oncol 5: 448-452.
36. Trigo Perez JM, Garrido Lopez P, Felip Font E, Isla Casado D, (2010) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clin Transl Oncol 12: 735-741.
37. Wahidi MM, Shofer SL, Sporn TA, Ernst A, (2009) Comparison of transbronchial lung biopsy yield between standard forceps and electrocautery hot forceps in swine. Respiration 79: 137-140.
38. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 3: 457-466.